Catalina Capital Group’s Pfizer PFE Stock Holding History

Catalina Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,013	Closed	-$319K	–	387
2024 Q3	$319K	Buy	11,013 +3,127	+40%	+$91.2K	0.11%	200
2024 Q2	$221K	Buy	+7,886	New	+$217K	0.08%	244

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalina Capital Group's PFE Position: Q4 2024 in Review

Catalina Capital Group sold out of Pfizer (PFE) in Q4 2024, closing a stake of 11,013 shares — an estimated $319K sold.

Catalina Capital Group first reported a position in PFE in Q2 2024 and held it in 2 quarters. The position peaked at $319K in Q3 2024. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Catalina Capital Group reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Catalina Capital Group sold 11,013 Pfizer shares in Q4 2024, an estimated $319K.
Catalina Capital Group first reported a position in Pfizer in Q2 2024 and held it in 2 quarters.
Catalina Capital Group's Pfizer position peaked at $319K in Q3 2024.
2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Catalina Capital Group's 13F filing for Q4 2024, filed 24 Jan 2025.